Today, EMA staff lowered the 28 EU flags and symbolically said goodbye to their London offices. Guido Rasi expressed his thanks to the UK for its contribution to the work of the Agency and for having been a gracious host of EMA since 1995. https://t.co/KpsBvaXt42
Today we are closing our London offices after almost a quarter of a century. Thank you, London for being such a gracious host! ema.europa.eu/en/about-us/hi….. https://t.co/8abqMcbROJ
📢 EMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine Moderna to prevent #COVID19 in people from 18 years of age: ema.europa.eu/en/news/ema-re….. https://t.co/BdvXanjOHN
EMA’s safety committee (PRAC) concludes that the benefits of the #COVID19Vaccine AstraZeneca still outweigh its risks despite possible link to rare blood clots associated with low levels of blood platelets.
👉Read more: ema.europa.eu/en/news/covid-….. https://t.co/0NO8kh5a48
Today we are saying ‘hallo’ to our new home. Thank you, #Amsterdam and the Netherlands, for the warm welcome! https://t.co/hiU4KWxtVc
📢 EMA has just recommended granting a conditional marketing authorisation for #COVID19vaccine Janssen to prevent #COVID19 in people from 18 years of age.
👉 ema.europa.eu/en/news/ema-re….. https://t.co/cKGKujrqYp
📢 EMA has just recommended granting a conditional marketing authorisation for the #COVID19vaccine developed by BioNTech/ Pfizer, to prevent #COVID19 in people from 16 years of age.
👉Read our press release: ema.europa.eu/en/news/ema-re….. https://t.co/4c5ujZKQ6b
📢 EMA has just recommended granting a conditional marketing authorisation for the #COVID19vaccine AstraZeneca to prevent #COVID19 in people from 18 years of age. 👉Read our press release:
EMA has received an application for conditional marketing authorisation for #COVID19 Vaccine Janssen:
After having received more data from the company, EMA is expecting Astra Zeneca to submit a conditional marketing application for its #COVID19vaccine next week. Possible conclusion - end of Jan, depending on data and evaluation progress. #EMAPublicMeeting2
EMA’s safety committee (#PRAC) has concluded its review of very rare cases of unusual blood clots with AstraZeneca #COVID19 vaccine.
Preliminary real-world data suggest that vaccines not only reduce #COVID19 disease and mortality but also viral transmission; more studies are needed to confirm this effect #EMAPublicMeeting3
EMA to move to Amsterdam bit.ly/2mMsmT5.. https://t.co/HzkIujRuJB
EMA receives the application for a conditional marketing authorisation of #COVID19 Vaccine AstraZeneca: ema.europa.eu/en/news/ema-re….. https://t.co/rpPoVEcNPk
EMA has started a rolling review of Sputnik V, a #COVID19vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology.
👉 ema.europa.eu/en/news/ema-st….. https://t.co/Bff87qJwOV
EMA’s safety committee (#PRAC) recommends adding ‘very rare cases of unusual blood clots with low blood platelets’ to the list of side effects for Janssen #vaccine.
Overall benefit-risk remains positive.
EMA’s safety committee (PRAC) is holding an extraordinary meeting on the investigation on #COVID19vaccine AstraZeneca and thromboembolic events. Once the meeting is over, we will communicate the conclusions on the Agency’s website
‼️ A press briefing on EMA’s safety committee (PRAC) conclusion on the review of #COVID19vaccine AstraZeneca and blood clots is planned at 4:00PM CET today.
Follow live: youtube.com/watch?v=R44xKG…..
Emer Cooke, EMA's Exec. Director: "EMA’s expert committee on the safety of medicines (#PRAC) has confirmed that the benefits of the AstraZeneca vaccine in preventing #COVID19 overall outweigh the risks of side effects.”
EMA’s safety committee (#PRAC) continues investigation of the #COVID19vaccine Astra Zeneca and thromboembolic events. Check out the latest updates:
EMA is monitoring very closely the data on the Indian variant. We are seeing promising evidence that mRNA vaccines would be able to neutralise this variant. #EMAPresser
The meeting of EMA’s human medicines committee (#CHMP) to discuss COVID-19 vaccine Moderna has started. We will communicate the outcome. Follow our updates on Twitter.
‼️ A press briefing on EMA’s safety committee (PRAC) review on the #COVID19Vaccine AstraZeneca and blood clots is planned at 5:00 PM CET today (time to be confirmed).
Follow live on YouTube: youtu.be/qYmP02SIQNI..
Emer Cooke, EMA's Exec. Director: EMA's scientific opinion paves the way for the first marketing authorisation of a #COVID19vaccine in the EU with the corresponding safeguards, controls and obligations.
EMA advises against the use of ivermectin medicines for the prevention and treatment of #COVID19 outside controlled clinical trials.